Therapeutic Strategies for Targeting Mononuclear Phagocytes in Cancer

被引：2

作者：

Dickens, David S. ^{[3
]}

Jubinsky, Paul T. ^{[1
,2
]}

机构：

[1] Albert Einstein Coll Med, Bronx, NY 10461 USA

[2] Childrens Hosp Montefiore, Bronx, NY USA

[3] Helen DeVos Childrens Hosp, Grand Rapids, MI USA

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2009年 / 31卷 / 01期

关键词：

tumor progression; cancer treatment; gene therapy; hypoxia; immune surveillance; metastasis; invasion; macrophage; dendritic cells; PULSED DENDRITIC CELLS; PHASE-II TRIAL; METASTATIC MELANOMA; BREAST-CANCER; MYELODYSPLASTIC SYNDROMES; GLIOBLASTOMA-MULTIFORME; TUMOR-REGRESSION; PRODRUG THERAPY; ONCOLOGY-GROUP; GENE-THERAPY;

D O I：

10.1097/MPH.0b013e31816e236a

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The initiation and progression of cancer is dependent oil factors both intrinsic and extrinsic to the malignant cells. Stromal, vascular endothelial. and inflammatory cells are the principal normal populations that support tumors by supplying factors and nutrients. The mononuclear phagocyte lineage. which includes monocytes, macrophages. and dendritic cells is of particular clinical interest because lineage members call enhance tumor angiogenesis and metastasis. or alternately contribute to turner destruction. Thus therapies that regulate these cells represent an innovative approach for improving patient survival in childhood cancer.

引用

页码：14 / 17

页数：4

共 47 条

[1] Anti-inflammatory properties of the novel antitumor agent yondelis (Trabectedin): Inhibition of macrophage differentiation and cytokine production [J].

Allavena, P ;

Signorelli, M ;

Chieppa, M ;

Erba, E ;

Bianchi, G ;

Marchesi, F ;

Olimpio, CO ;

Bonardi, C ;

Garbi, A ;

Lissoni, A ;

de Brand, F ;

Jimeno, J ;

D'Incalci, M .

CANCER RESEARCH, 2005, 65 (07) :2964-2971

[2]

Azenshtein E, 2002, CANCER RES, V62, P1093

[3] Antivascular therapy of cancer: DMXAA [J].

Baguley, BC .

LANCET ONCOLOGY, 2003, 4 (03) :141-148

[4] Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme [J].

Baumann, F ;

Bjeljac, M ;

Kollias, SS ;

Baumert, BG ;

Brandner, S ;

Rousson, V ;

Yonekawa, Y ;

Bernays, RL .

JOURNAL OF NEURO-ONCOLOGY, 2004, 67 (1-2) :191-200

[5] A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours [J].

Blay, JY ;

Le Cesne, A ;

Verweij, J ;

Scurr, M ;

Seynaeve, C ;

Bonvalot, S ;

Hogendoorn, P ;

Jimeno, J ;

Evrard, V ;

van Glabbeke, M ;

Judson, I .

EUROPEAN JOURNAL OF CANCER, 2004, 40 (09) :1327-1331

[6] A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies [J].

Bouscary, D ;

Legros, L ;

Tulliez, M ;

Dubois, S ;

Mahe, B ;

Beyne-Rauzy, O ;

Quarre, MC ;

Vassilief, D ;

Varet, B ;

Aouba, A ;

Gardembas, M ;

Giraudier, S ;

Guerci, A ;

Rousselot, P ;

Gaillard, F ;

Moreau, A ;

Rousselet, MC ;

Ifrah, N ;

Fenaux, P ;

Dreyfus, F .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (05) :609-618

[7] Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma [J].

Braybrooke, JP ;

Slade, A ;

Deplanque, G ;

Harrop, R ;

Madhusudan, S ;

Forster, MD ;

Gibson, R ;

Makris, A ;

Talbot, DC ;

Steiner, J ;

White, L ;

Kan, O ;

Naylor, S ;

Carroll, MW ;

Kingsman, SM ;

Harris, AL .

CLINICAL CANCER RESEARCH, 2005, 11 (04) :1512-1520

[8]

Cann SAH, 2003, POSTGRAD MED J, V79, P672

[9] Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study [J].

Chanan-Khan, Asher ;

Miller, Kena C. ;

Musial, Laurie ;

Lawrence, David ;

Padmanabhan, Swaminathan ;

Takeshita, Kenichi ;

Porter, Carl W. ;

Goodrich, David W. ;

Bernstein, Zale P. ;

Wallace, Paul ;

Spaner, David ;

Mohr, Alice ;

Byrne, Catriona ;

Hernandez-Ilizaliturri, Francisco ;

Chrystal, Cynthia ;

Starostik, Petr ;

Czuczman, Myron S. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5343-5349

[10] Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme [J].

Chang, SM ;

Lamborn, KR ;

Malec, M ;

Larson, D ;

Wara, W ;

Sneed, P ;

Rabbitt, J ;

Page, M ;

Nicholas, MK ;

Prados, MD .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (02) :353-357

← 1 2 3 4 5 →